SGPSpyGlass Pharma, Inc.vs its industry peers
A metric-by-metric comparison of SpyGlass Pharma, Inc. against Surgical & Medical Instruments & Apparatus — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGPThis | $979M#8 | — | 4.2x#8 | — | — | -36.7%#14 | — | -17.2%#8 | — | — | — | — |
| ATEC | $1.6B#1 | — | — | 2.1x#5 | 25.0%#6 | 11.6%#8 | -10.7%#6 | — | -18.5%#7 | 6#3 | -30.0%#11 | — |
| KMTS | $1.4B#2 | — | 6.5x#11 | 15.2x#14 | 59.0%#3 | -15.6%#12 | -141.6%#15 | -59.2%#14 | -59.5%#11 | 4#7 | 2.9%#8 | — |
| TNDM | $1.2B#3 | — | 9.2x#13 | 1.2x#2 | 7.9%#14 | -113.2%#15 | -18.5%#10 | -157.0%#15 | -26.3%#9 | 3#9 | 41.3%#4 | — |
| IART | $1.2B#4 | — | 1.1x#1 | 0.7x#1 | 1.5%#15 | -7389.9%#16 | -30.2%#12 | -49.5%#13 | -32.1%#10 | 6#3 | 2.0%#9 | — |
| AORT | $1.2B#5 | — | 2.6x#3 | 2.6x#8 | 13.6%#12 | 173.1%#1 | 7.6%#3 | 2.2%#4 | 3.0%#2 | 5#6 | -40.2%#14 | 0.3%#2 |
| PRCT | $1.1B#6 | — | 3.3x#5 | 3.6x#9 | 37.2%#5 | -4.5%#9 | -33.7%#13 | -0.0%#5 | -63.4%#12 | 2#11 | -47.8%#15 | — |
| IRMD | $1.1B#7 | 46.3x#1 | 10.4x#14 | 12.6x#13 | 14.4%#11 | 16.9%#6 | 31.2%#1 | 22.1%#2 | — | — | 17.4%#6 | 1.4%#1 |
| BBNX | $965M#9 | — | 3.8x#7 | 9.6x#12 | 53.9%#4 | -33.7%#13 | -71.5%#14 | -28.6%#12 | — | — | -7.1%#10 | — |
| SIBN | $810M#10 | — | 4.4x#9 | 4.0x#10 | 20.2%#7 | 38.8%#3 | -11.1%#7 | -10.4%#6 | -12.0%#4 | 6#3 | 23.2%#5 | — |
| MDXG | $684M#11 | 117.3x#2 | 3.2x#4 | 1.6x#3 | 20.0%#8 | 14.5%#7 | 15.3%#2 | 22.5%#1 | 48.1%#1 | 8#1 | -32.5%#12 | — |
| SSII | $661M#12 | — | 12.4x#15 | 15.6x#15 | 105.7%#2 | 36.7%#4 | -19.3%#11 | -22.7%#11 | -20.1%#8 | — | -38.2%#13 | — |
| ANGO | $635M#13 | — | 3.7x#6 | 2.0x#4 | 9.5%#13 | -8.1%#11 | -12.5%#8 | -21.5%#9 | -16.5%#6 | 4#7 | 42.0%#3 | — |
| KIDS | $570M#14 | — | 1.7x#2 | 2.4x#7 | 15.4%#10 | -4.8%#10 | -16.6%#9 | -11.5%#7 | -8.6%#3 | 3#9 | 13.4%#7 | — |
| DCTH | $564M#15 | 812.5x#3 | 4.7x#10 | 6.6x#11 | 129.1%#1 | 110.2%#2 | 0.8%#4 | 2.2%#3 | — | 8#1 | 45.2%#2 | — |
| CERS | $535M#16 | — | 7.6x#12 | 2.3x#6 | 16.1%#9 | 25.3%#5 | -3.7%#5 | -22.3%#10 | -15.5%#5 | — | 115.9%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 3841). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice